MedTrace Logo

Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients

NCT06040944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2023-09-18

No results posted yet for this study

Summary

The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.

The study population consisted of three groups: Group A (n = 21): schizophrenic patients who have been taking "prolactin inducing" antipsychotics for at least 1 year, Group B (n = 21): schizophrenic patients who have been taking "prolactin sparing" antipsychotics for at least 1 year and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year.

The study groups underwent an assessment of periodontal condition in terms of pocket depth (PD), clinical attachment loss (CAL), gingival recession, tooth mobility, and bleeding on probing (BOP). Also, bone mineral density was evaluated using DEXA scans and the serum prolactin level was measured by automated immunoassay.

Conditions

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Periodontal Diseases

Interventions

DRUG

antipsychotic drugs inducing hyperprolactinemia

not exposed

Sponsors & Collaborators

  • Fayoum University

    lead OTHER

Principal Investigators

  • Rania H Shalby, phd · Faculty of Dentistry-Fayoum University

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-10-01
Completion
2022-11-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06040944 on ClinicalTrials.gov